Joseph P. Hagan
2011 - Orexigen Therapeutics
In 2011, Joseph P. Hagan earned a total compensation of $2.1M as Chief Business Officer at Orexigen Therapeutics, a 112% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $259,000 |
|---|---|
| Option Awards | $1,432,066 |
| Salary | $370,000 |
| Other | $7,470 |
| Total | $2,068,536 |
Hagan received $1.4M in option awards, accounting for 69% of the total pay in 2011.
Hagan also received $259K in non-equity incentive plan, $370K in salary and $7.5K in other compensation.
Rankings
In 2011, Joseph P. Hagan's compensation ranked 3,165th out of 10,747 executives tracked by ExecPay. In other words, Hagan earned more than 70.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,165 out of 10,747 | 71st |
Division Manufacturing | 1,103 out of 3,960 | 72nd |
Major group Chemicals And Allied Products | 217 out of 1,033 | 79th |
Industry group Drugs | 121 out of 781 | 85th |
Industry Pharmaceutical Preparations | 102 out of 571 | 82nd |
Source: SEC filing on April 30, 2014.
Hagan's colleagues
We found five more compensation records of executives who worked with Joseph P. Hagan at Orexigen Therapeutics in 2011.
2011
Michael Narachi
Orexigen Therapeutics
Chief Executive Officer
2011
Heather Turner
Orexigen Therapeutics
General Counsel
2011
Preston Klassen
Orexigen Therapeutics
Head of Global NB32 Program and Senior Vice President, Product Development
2011
Mark Booth
Orexigen Therapeutics
Chief Commercial Officer
2011
Graham Cooper
Orexigen Therapeutics
Chief Financial Officer
News
Regulus Therapeutics CEO Joseph Hagan's 2021 pay falls 22% to $1.8M
April 27, 2022
Regulus Therapeutics CEO Joseph Hagan's 2020 pay rises 16% to $2.3M
April 30, 2021
Regulus Therapeutics CEO Joseph Hagan's 2019 pay slips 14% to $2M
April 29, 2020
Regulus Therapeutics CEO Joseph Hagan's 2018 pay jumps 22% to $2.3M
July 1, 2019